Physician profile
Patrick A Cockerill
NPI 1124313184
$2,457.06
in general payments reported to CMS, 2019-2025
24 companies · $896 in 2025
The $896 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2020: $16.86 · 2021: $311 · 2022: $142 · 2023: $239 · 2024: $582 · 2025: $896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,717.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $543.20 | 2019-2025 | Erleada, Akeega, Balversa |
| Dendreon Pharmaceuticals LLC | $245.16 | 2019-2025 | Provenge |
| Sumitomo Pharma America, INC. | $192.85 | 2023-2025 | Orgovyx |
| Intuitive Surgical, INC. | $149.34 | 2021 | |
| Abbvie INC. | $148.68 | 2022-2025 | Botox |
| Calyxo, INC. | $141.67 | 2024 | Cvac Aspiration System |
| Axonics, INC. | $129.80 | 2022-2023 | Axonics |
| Olympus America INC. | $114.27 | 2025 | Itind System |
| Myriad Genetic Laboratories, INC. | $104.03 | 2024-2025 | Prolaris |
| Novartis Pharmaceuticals Corporation | $91.73 | 2024-2025 | |
| Blue Earth Diagnostics | $88.05 | 2021-2025 | Posluma |
| Urogen Pharma, INC. | $80.65 | 2024-2025 | |
| Astellas Pharma US INC | $78.72 | 2019-2025 | Xtandi |
| Tolmar, INC. | $65.00 | 2023-2025 | Eligard, Jatenzo |
| Allergan, INC. | $62.07 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $36.25 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $30.11 | 2025 | Lynparza |
| Foundation Medicine, INC. | $30.01 | 2023 | Foundationone Cdx |
| Procept Biorobotics Corporation | $29.39 | 2022 | |
| Endo Pharmaceuticals INC. | $24.99 | 2019 | |
| Pfizer INC. | $19.28 | 2022 | |
| Boston Scientific Corporation | $18.18 | 2024 | Tria Firm |
| Tolmar Pharmaceuticals, INC. | $17.42 | 2022 | |
| Biotissue Holdings INC. | $16.21 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Cockerill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.